Mervyn Turner had over 25 years of experience at Merck Research Laboratories, in research and development, licensing and business development, emerging markets analysis, and strategy development and implementation. For seven years he was head of world-wide licensing and external research at Merck, and became Merck’s first Chief Strategy Officer and a member of the senior executive team. He retired from Merck in 2011 and currently operates his own consulting business. He serves on the Board of EnGeneIC and as an Advisor to Bay City Capital, Adagene, Bridge Medicines and the Lazard Healthcare Group. He is a member of the SAB for Spinogenix and Blade Therapeutics.